Fueled by our AI-powered technology platform, we have five differentiated programs in IND-enabling studies* supported by preclinical data showing their potential first or best-in-class profiles. Learn more below about each of these transformative product candidates:
Our masked anti-CD47 IgG1 SAFEbody® is differentiated by its strong antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity designed to realize the full potential of anti-CD47 therapy for both hematologic and solid tumor indications.
Preclinical data demonstrated that ADG153 IgG1 was well tolerated, did not induce human hemagglutination and significantly reduced anemia-related and antigen sink liabilities. Results also showed that ADG153 IgG1 demonstrated greater anti-tumor activity than a benchmark antibody which is in IgG4 format.
Our HER2xCD3 POWERbody is masked on both arms with an impressively high therapeutic index relative to its parental non-masked TCE in both HER2 high and low expressing solid tumors, supporting its development for HER2-expressing solid tumors as a single agent and in combination with other immune modulating agents.
Preclinical data demonstrated the excellent safety profile of ADG138, including 100-fold greater reduction in cytokine release compared to its parental TCE. Results showed that ADG138 has potent anti-tumor activity in HER2 high and low expressing tumors, as well as resistant/refractory tumors, relative to a benchmark. ADG138 also had synergistic anti-tumor activity in HER2 positive tumors when combined with anti-CD137 or anti-PD-1 therapy, or tumor targeted CD28 bispecific antibody.
Our bispecific CD20xCD3 T-cell engager POWERbody integrates SAFEbody precision masking technology to minimize cytokine release syndrome (CRS) and on-target/off-tumor toxicities for an increased therapeutic index. The anti-CD20 arm of ADG152 has enhanced the binding to CD20, while its anti-CD3 arm has tailor made affinity for CD3 using SAFEbody technology.
Preclinical data showed ADG152 resulted in significantly less cytokine induction (as measured by IFN-γ and IL-2 levels) than a benchmark antibody when administered at a 100-fold higher dose (30 mg/kg). ADG152 also resulted in dose-dependent anti-tumor activity with almost complete tumor growth inhibition when dosed at 1.5 mg/kg. ADG152 induced strong and sustained B-cell depletion across different dose levels, and it demonstrated improved pharmacokinetics in monkeys versus the benchmark, with approximately a 2-fold longer half-life and approximately an 8-fold higher AUC after a single intravenous injection.
*A fifth program in the IND-enabling phase has not been disclosed.